Dynavax Technologies News
A stock that investors may want to consider dropping is Discovery Laboratories Inc. (DSCO)
Dynavax Technologies commenced a new phase III study (HBV-23) on its hepatitis B vaccine candidate, Heplisav-B
Dynavax Technologies Corporation today announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study was ...
These small-cap names could cause some big upsets.
Dynavax Technologies reported a loss of 9 cents per share in the fourth quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 7 cents.